Verastem Inc
$ 6.34
0.16%
16 Apr - close price
- Market Cap 556,924,000 USD
- Current Price $ 6.34
- High / Low $ 6.50 / 6.18
- Stock P/E N/A
- Book Value 0.74
- EPS -3.03
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -14.80 %
- 52 Week High 11.25
- 52 Week Low 4.01
About
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Analyst Target Price
$16.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-04 | 2025-08-07 | 2025-05-07 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.4592 | -1.35 | -0.62 | -0.79 | -0.6 | -0.6 | -0.31 | -1.26 | -1.02 | -0.75 | -1.37 | -0.08 |
| Estimated EPS | -0.4967 | -0.87 | -0.88 | -0.775 | -0.7367 | -0.74 | -0.95 | -1 | -0.62 | -0.84 | -1.06 | -0.08 |
| Surprise | 0.0375 | -0.48 | 0.26 | -0.015 | 0.1367 | 0.14 | 0.64 | -0.26 | -0.4 | 0.09 | -0.31 | 0 |
| Surprise Percentage | 7.5498% | -55.1724% | 29.5455% | -1.9355% | 18.5557% | 18.9189% | 67.3684% | -26% | -64.5161% | 10.7143% | -29.2453% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VSTM
2026-04-16 11:10:27
Mizuho Securities has reiterated its Buy rating for Verastem (VSTM.US), maintaining a target price of $16. This continued positive outlook suggests the firm's confidence in Verastem's future performance.
2026-04-14 06:39:18
A new report by DataM Intelligence projects the global PI3K Inhibitor Drug Class Market to reach US$2.3 Billion by 2033, growing at a CAGR of 5.5% between 2026 and 2033. The report highlights key market dynamics, regional growth trends, and recent industry developments, including Novartis's acquisition of a PI3Kα inhibitor and advancements in clinical development by iOnctura and Roche. It also details market segmentation and lists key players such as Novartis AG, Gilead Sciences, and Pfizer Inc.
2026-04-10 23:10:27
BTIG Research has reiterated a "Buy" rating for Verastem (NASDAQ:VSTM) with a $19.00 price target, suggesting a potential upside of 254.81%. Other analysts maintain varied ratings, with the stock holding a consensus "Moderate Buy" rating and an average target price of $16.60. Despite recent weakness shown by its trading below key moving averages, institutional investors hold a significant stake, although insiders have sold shares recently.
2026-04-10 18:40:27
HC Wainwright & Co. has reiterated its Buy rating for Verastem (VSTM), maintaining a price target of $18.00, reflecting confidence in the company's future performance. This decision was made by analyst Andres Y. Maldonado and indicates a stable outlook for the stock. Verastem Inc. is a biopharmaceutical company focused on developing novel anticancer agents. Wall Street analysts forecast an average target price of $16.71 for VSTM, implying a significant upside from its current price.
2026-04-10 18:40:27
BTIG has reaffirmed its 'Buy' rating for Verastem (VSTM) with an unchanged price target of $19.00. This reiteration aligns with a consistent bullish outlook from multiple analysts, indicating strong confidence in the biopharmaceutical company's pipeline and future performance. The average analyst price target for VSTM stands at $16.71, suggesting a significant upside of 212.42% from its current price.
2026-04-10 15:09:46
Verastem Oncology has announced two-year median follow-up data from its Phase 2 RAMP 201 clinical trial for AVMAPKI® FAKZYNJA® combination therapy in recurrent low-grade serous ovarian cancer (LGSOC). The data, presented at the SGO 2026 Annual Meeting, showed sustained clinical benefits and a well-tolerated safety profile, with efficacy consistent with the primary analysis. The company highlights the therapy's durability and clinical meaningfulness, particularly for patients with and without KRAS mutations.
